Washington University in St. Louis

Washington University Open Scholarship
Biology Faculty Publications & Presentations

Biology

11-6-2014

Ribosomes Left in the Dust: Diverse Strategies for
Peptide-Mediated Translation Stalling
Benjamin H. Hudson
Hani S. Zaher
hzaher@wustl.edu

Follow this and additional works at: https://openscholarship.wustl.edu/bio_facpubs
Part of the Biochemistry Commons, Biology Commons, and the Molecular Biology Commons
Recommended Citation
Hudson, Benjamin H. and Zaher, Hani S., "Ribosomes Left in the Dust: Diverse Strategies for Peptide-Mediated Translation Stalling"
(2014). Biology Faculty Publications & Presentations. 54.
https://openscholarship.wustl.edu/bio_facpubs/54

This is brought to you for free and open access by the Biology at Washington University Open Scholarship. It has been accepted for inclusion in Biology
Faculty Publications & Presentations by an authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

Title: Ribosomes left in the dust: diverse strategies for peptidemediated translation stalling

Authors: Benjamin H. Hudson and Hani S. Zaher*

Affiliations: Department of Biology, Washington University in St. Louis, St. Louis, MO, USA
63130.

*Contact: hzaher@wustl.edu
Department of Biology
Washington University in St. Louis
Campus Box 1137, One Brookings Drive
St. Louis, MO, USA 63130
Phone: (314) 935-7662
Fax: (314) 935-4432

Summary
In two recent papers, Arenz et al. (2014) and Bischoff et al. (2014) provide structural insights
into drug-induced, peptide-mediated stalling of the ribosome.

Main Text
Ribosomes are fast, accurate, and highly processive enzymes. While the ribosome
translates the vast majority of the proteome efficiently, certain polypeptide sequences stall the
ribosome either on their own or in combination with a small-molecule (Cruz-Vera et al., 2011).
Moreover, a number of biological processes have evolved to rely on these peptide-mediated
stalling events for their functionality, including the induction of erythromycin/macrolide
resistance (ErmC), regulation of intracellular tryptophan levels (TnaC), and modulation of the
SecA secretory system (SecM). Over the years, a number of studies have identified many of the
key residues in both the peptides and ribosome exit tunnel that contribute to pausing. However,
what has remained unclear is how these interactions affect the structure of the ribosome and in
particular the peptidyl-transferase center (PTC) to prevent further elongation or termination. Two
recent papers in Molecular Cell (Arenz et al 2014) and Cell Reports (Bischoff et al 2014) harness
the power of recent advances in Cryo-EM to address these issues. Both groups report highresolution cryo-EM map of peptide-stalled ribosomes that help to shed light on the interactions
and mechanisms that nascent peptides utilize to mediate these events.
Building on their previous Cryo-EM studies of the erythromycin-resistance leader
sequence ErmBL, Arenz and colleauges now address how the related ErmCL, which contains the
well-conserved IFVI stalling sequence found in many erythromycin-resistance genes, is able to

modulate interactions between the nascent peptide and exit tunnel residue and how these
interactions lead to inactivation of the PTC (Arenz et al 2014b) (Arenz et al., 2014). They find
that in contrast to ErmBL, the ErmCL peptide follows a distinct path in the exit tunnel, bringing
it much closer to, and even contacting, the bound erythromycin at the bulky cladinose ring of
erythromycin and F7 of the ErmCL peptide (Fig. 1, top left) (Arenz et al 2014b). This agreed
well with previous results demonstrating that macrolides without cladinose rings abrogate
stalling (Vazquez-Laslop et al., 2008). In addition to contacting erythromycin, the C-terminal
fragment of the peptide interacts with rRNA residues U2506 and U2586 via the conserved IFVI
motif. They also observed interactions between the N-terminus of the peptide and residues in the
exit tunnel previously identified by mutagenesis, although the density is too poor to definitively
assign. With regard to how ErmCL is able to modulate the PTC to prevent further peptide
elongation, Arenz et al find that a number of residues important for A-site tRNA binding and
accommodation including U2585, A2602, and U2506 are stabilized by the ErmCL peptide in
conformations that are distinct from those of the accommodated, non-accommodated, or ErmBL
structures (Fig. 1, top right). These stabilized conformations appear to be sufficient to preclude
proper positioning of the incoming A-site tRNA and explain why no bound A-site tRNA is
observed in their structure.
In contrast to ErmCL, the TnaC peptide has evolved an entirely different mechanism to
stall ribosomes. Previous mutagenesis and structural studies had shed light on many of the key
residues involved in peptide-mediated stalling (Cruz-Vera et al., 2006; Seidelt et al., 2009).
However, it remained unclear precisely where the tryptophan (Trp) molecule bound to the
ribosome and how this contributed to inactivation of the PTC and translation blockade (Martinez
et al., 2014). To decipher this, Bischoff et al, utilized an in vivo purification scheme to isolate a

large quantity of nearly homogenous TnaC-stalled ribosomes (Bischoff et al 2014).
Unexpectedly, the resulting Cryo-EM structure revealed not one, but two Trp molecules bound
in the exit tunnel. Both Trp molecules bind to pockets created by interactions between the
nascent TnaC peptide and the rRNA (Fig. 1, left middle panel). The first Trp binds between V20
and I19 of the peptide and U2586 of the ribosome. The second Trp binds in a kink of the peptide
at N17 and K18, and U2609 and A752 in the 23S rRNA. The second Trp also makes contact
with A2058 and A2059, residues important for organizing the PTC. Together these interactions
are sufficient to stabilize A2058, A2059, and A2602 in non-productive positions within the PTC
and prevent RF2 binding and peptide release (Fig. 1 right middle panel). Yet precisely how these
interactions conspire to stop translation remains enigmatic. Previous experiments hint at the
importance of the slowly reacting codon pair (Pro-Stop), however, the precise ordering of the
conformational changes and tryptophan binding requires future analysis (Cruz-Vera et al., 2006;
Martinez et al., 2014).
Two long-standing questions of peptide-mediated stalling have been how the peptides
specifically interact with the exit tunnel and/or bound small molecules and how these
interactions lead to a non-functional PTC. Here, Arenz, Bischoff, and colleagues demonstrate
that both exit tunnel binding and PTC inactivation can occur through a variety of mechanisms.
For ErmCL, erythromycin binds first, which likely provides the necessary contact between rRNA
residues in the exit tunnel and the nascent peptide to halt translation. In contrast, the TnaC
peptide slows translation on its own, potentially allowing sufficient time for the two Trp
molecules to bind the exit tunnel and completely stall the ribosome (Bischoff et al 2014) (CruzVera et al., 2006; Martinez et al., 2014). Interestingly, these peptides represent just two examples
from among a wide variety of known ribosome-stalling peptides. For instance, ErmBL, does not

rely on the structural contacts between the bound erythromycin and also stabilizes a unique
conformation of the PTC that allows the A-site tRNA to bind but prevents peptide bond
formation (Arenz et al., 2014). And while there is not yet a definitive high-resolution structure of
SecM-mediated stalling, previous Cryo-EM studies suggest that the elongating peptide first
interacts with the early exit tunnel and then with the constriction point imposed by large subunit
proteins L4 and L22 (Fig. 1, bottom left and right) (Bhushan et al., 2011). Upon continued
translation, the peptide gradually becomes more compacted, stabilized, and ultimately stalled.
Thus, it seems that no two peptides stall the ribosome in the same manner. Moreover,
biochemical and ribosomal profiling studies have identified a number of peptide motifs that slow
translation to varying degrees both in vitro and in vivo (Elgamal et al., 2014; Woolstenhulme et
al., 2013). Whether these effects are mediated solely by interactions between the exit tunnel and
nascent peptide or in combination with differences in tRNA abundance and reactivity remains
unclear. However, it will be exciting to explore how proteins have evolved to utilize this
continuum of translational pausing as a means of modulating gene expression and biological
regulation.

Figure Legends
Figure 1. Schematic of the interactions between the indicated nascent peptide, ligands and the
exit tunnel of the ribosome (left). Resulting conformational changes to the peptidyl transferase
center from these interactions (right).
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